IL230687A0 - Methods for diagnosing cancer by characterizing cancer cells associated with pleural fluids or serum - Google Patents
Methods for diagnosing cancer by characterizing cancer cells associated with pleural fluids or serumInfo
- Publication number
- IL230687A0 IL230687A0 IL230687A IL23068714A IL230687A0 IL 230687 A0 IL230687 A0 IL 230687A0 IL 230687 A IL230687 A IL 230687A IL 23068714 A IL23068714 A IL 23068714A IL 230687 A0 IL230687 A0 IL 230687A0
- Authority
- IL
- Israel
- Prior art keywords
- pleural
- characterization
- methods
- tumor cells
- cells associated
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512576P | 2011-07-28 | 2011-07-28 | |
| PCT/US2012/048452 WO2013016600A2 (en) | 2011-07-28 | 2012-07-27 | Methods and reagents for diagnosing conditions and characterization of tumor cells associated with serous fluids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL230687A0 true IL230687A0 (en) | 2014-03-31 |
Family
ID=46650901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL230687A IL230687A0 (en) | 2011-07-28 | 2014-01-28 | Methods for diagnosing cancer by characterizing cancer cells associated with pleural fluids or serum |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140295426A1 (enExample) |
| EP (1) | EP2737317A2 (enExample) |
| JP (1) | JP2014521958A (enExample) |
| IL (1) | IL230687A0 (enExample) |
| TW (1) | TW201312117A (enExample) |
| WO (1) | WO2013016600A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6238856B2 (ja) * | 2014-08-25 | 2017-11-29 | シスメックス株式会社 | 尿中異型細胞の分析方法、尿分析装置および体液中異型細胞の分析方法 |
| CA3000438C (en) * | 2015-09-28 | 2024-05-14 | The Governing Council Of The University Of Toronto | Device for magnetic profiling of particles in a flow |
| US10696961B2 (en) | 2017-12-01 | 2020-06-30 | Global Life Sciences Solutions Usa Llc | Magnetic cell isolation techniques |
| CA3082861A1 (en) * | 2017-12-01 | 2019-06-06 | General Electric Company | Methods for cell enrichment and isolation |
| EP4073511A4 (en) * | 2019-12-12 | 2024-01-17 | University of Miami | MATERIALS AND METHODS FOR DETECTING EXTRACELLULAR VESICLES |
| EP4139440B1 (en) | 2020-04-22 | 2026-08-19 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| WO2021226061A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| EP4146793A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| CA3195019A1 (en) | 2020-10-06 | 2022-04-14 | Maria Fardis | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| JP2024501452A (ja) | 2020-12-11 | 2024-01-12 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｂｒａｆ阻害剤及び／またはｍｅｋ阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療 |
| JP2023554395A (ja) | 2020-12-17 | 2023-12-27 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療 |
| US20240123067A1 (en) | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
| JP2024501845A (ja) | 2020-12-31 | 2024-01-16 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス |
| JP2024509184A (ja) | 2021-03-05 | 2024-02-29 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍保存及び細胞培養組成物 |
| TW202304480A (zh) | 2021-03-19 | 2023-02-01 | 美商艾歐凡斯生物治療公司 | 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法 |
| EP4314253A2 (en) | 2021-03-25 | 2024-02-07 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
| AU2022263418A1 (en) | 2021-04-19 | 2023-10-26 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| US20240269180A1 (en) | 2021-05-17 | 2024-08-15 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
| CA3226942A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
| CA3231018A1 (en) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
| US20250000903A1 (en) | 2021-09-24 | 2025-01-02 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
| US20230187042A1 (en) | 2021-10-27 | 2023-06-15 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| AU2022388729A1 (en) | 2021-11-10 | 2024-05-16 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| JP2025503987A (ja) | 2022-01-28 | 2025-02-06 | アイオバンス バイオセラピューティクス，インコーポレイテッド | ペイロードを発現するように操作された腫瘍浸潤リンパ球 |
| EP4507704A1 (en) | 2022-04-15 | 2025-02-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
| WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
| EP4565683A1 (en) | 2022-08-01 | 2025-06-11 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| EP4612277A1 (en) | 2022-11-04 | 2025-09-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
| WO2024112571A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
| IL325907A (en) | 2023-07-13 | 2026-03-01 | Iovance Biotherapeutics Inc | Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes |
| WO2025019790A1 (en) | 2023-07-19 | 2025-01-23 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc |
| IL328125A (en) | 2023-11-06 | 2026-06-01 | Iovance Biotherapeutics Inc | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
| WO2026050217A2 (en) | 2024-08-27 | 2026-03-05 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939240A (en) | 1983-03-04 | 1990-07-03 | Health Research, Inc. | Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy |
| JPH0763389B2 (ja) * | 1986-10-28 | 1995-07-12 | 協和醗酵工業株式会社 | 抗ヒト中皮細胞単クローン性抗体 |
| CA2065874C (en) | 1989-09-15 | 2001-12-11 | Joseph P. Brown | Hybridoma ct43 producing a monoclonal antibody to a mucin epitope of colorectal cancer |
| CA2144750A1 (en) | 1992-09-17 | 1994-03-31 | Rolf Stahel | Tumor-specific antibodies and antigen |
| NO180658C (no) * | 1994-03-10 | 1997-05-21 | Oeystein Fodstad | Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner |
| US6660159B1 (en) | 1996-06-07 | 2003-12-09 | Immunivest Corporation | Magnetic separation apparatus and methods |
| US6136182A (en) | 1996-06-07 | 2000-10-24 | Immunivest Corporation | Magnetic devices and sample chambers for examination and manipulation of cells |
| AU3374597A (en) | 1996-06-07 | 1998-01-05 | Immunivest Corporation | Magnetic separation employing external and internal gradients |
| US6790366B2 (en) | 1996-06-07 | 2004-09-14 | Immunivest Corporation | Magnetic separation apparatus and methods |
| US6890426B2 (en) | 1996-06-07 | 2005-05-10 | Immunivest Corporation | Magnetic separation apparatus and methods |
| WO1999041613A1 (en) | 1998-02-12 | 1999-08-19 | Immunivest | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
| US7282350B2 (en) | 1998-02-12 | 2007-10-16 | Immunivest Corporation | Labeled cell sets for use as functional controls in rare cell detection assays |
| US6623982B1 (en) | 1999-07-12 | 2003-09-23 | Immunivest Corporation | Increased separation efficiency via controlled aggregation of magnetic nanoparticles |
| JP3766064B2 (ja) | 2001-02-12 | 2006-04-12 | イムニベスト・コーポレイション | 光学分析用の標本試料を収容するためのカートリッジ |
| WO2003019141A2 (en) * | 2001-08-23 | 2003-03-06 | Immunivest Corporation | Analysis of circulating tumor cells, fragments, and debris |
| GB2395270B (en) * | 2002-11-14 | 2006-08-16 | Univ Nottingham | Tumour marker proteins and uses thereof |
| EP1723428A2 (en) * | 2004-02-19 | 2006-11-22 | Yale University Corporation | Identification of cancer protein biomarkers using proteomic techniques |
| US20060024824A1 (en) * | 2004-07-16 | 2006-02-02 | Steven Woodside | Magnetic cell separation method |
| US7846743B2 (en) * | 2005-04-21 | 2010-12-07 | California Institute Of Technology | Uses of parylene membrane filters |
| EP1888238B1 (en) * | 2005-04-21 | 2014-08-13 | California Institute of Technology | Parylene membrane filters |
| FR2896881B1 (fr) * | 2006-01-31 | 2008-04-18 | Biomerieux Sa | Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie |
| AU2007288620B2 (en) * | 2006-08-23 | 2012-08-30 | Korea Research Instititute Of Bioscience And Biotechnology | A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma |
| EP2037265A1 (en) * | 2007-09-17 | 2009-03-18 | Adnagen AG | Solid phase cell isolation and/or enrichment method |
| WO2010102177A1 (en) * | 2009-03-06 | 2010-09-10 | Becton, Dickinson And Company | Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer |
-
2012
- 2012-07-27 WO PCT/US2012/048452 patent/WO2013016600A2/en not_active Ceased
- 2012-07-27 TW TW101127107A patent/TW201312117A/zh unknown
- 2012-07-27 US US14/235,185 patent/US20140295426A1/en not_active Abandoned
- 2012-07-27 EP EP12746193.7A patent/EP2737317A2/en not_active Withdrawn
- 2012-07-27 JP JP2014523039A patent/JP2014521958A/ja active Pending
-
2014
- 2014-01-28 IL IL230687A patent/IL230687A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2737317A2 (en) | 2014-06-04 |
| WO2013016600A2 (en) | 2013-01-31 |
| US20140295426A1 (en) | 2014-10-02 |
| WO2013016600A3 (en) | 2013-04-18 |
| JP2014521958A (ja) | 2014-08-28 |
| TW201312117A (zh) | 2013-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2841603A4 (en) | METHODS OF ASSESSING THE STATUS OF LUNG CANCER | |
| PL2714926T3 (pl) | Biomarkery raka płuca | |
| IL239196A0 (en) | Molecular diagnosis of cancer | |
| ZA201203010B (en) | Diagnostic methods for determining prognosis of non-small cell lung cancer | |
| EP2668295A4 (en) | METHODS OF DETECTING LUNG CANCER | |
| IL235459A0 (en) | Ways to treat non-small cell lung cancer | |
| IL237038A0 (en) | Epcam aptamer for detection of cancer stem cells | |
| SG11201510210XA (en) | Methods for detecting prostate cancer | |
| ZA201408120B (en) | Diagnostic gene marker panel for colorectal cancer | |
| SMT202400193T1 (it) | Nuovi metodi per bersagliare cellule staminali cancerose | |
| IL238639A0 (en) | Methods for using biomarkers to treat cancer by regulating bcl2 expression | |
| GB201012590D0 (en) | Methods for diagnosing cancer | |
| EP2833149A4 (en) | METHOD FOR DETECTING THE MALIGNANCE DEGREE OF A CIRCULATING TUMOR CELL UNIT AND KIT THEREFOR | |
| EP2965086A4 (en) | Methods of detecting prostate cancer | |
| PL2734636T3 (pl) | Bio-markery mikro-rna do identyfikacji ryzyka i/lub diagnozowania nowotworu płuc | |
| ZA201309254B (en) | Method for treating non-small cell lung cancer | |
| EP3094976A4 (en) | Cell surface prostate cancer antigen for diagnosis | |
| IL232466A (en) | Preparations and Methods for Prostate Cancer Analysis | |
| EP3058101A4 (en) | Serum mirnas for the prognosis of prostate cancer | |
| SG11201402115TA (en) | Methods for diagnosis and/or prognosis of gynecological cancer | |
| ZA201203011B (en) | Diagnostic methods for determining prognosis of non-small cell lung cancer | |
| GB2510539B (en) | Biomarkers of cancer | |
| EP2932273A4 (en) | METHODS OF DIAGNOSING AND TREATING PROSTATE CANCER | |
| WO2012106368A9 (en) | Methods for inhibiting prostate cancer | |
| EP2732287A4 (en) | METHOD FOR THE DIAGNOSIS OF CANCER |